下一代定序试剂盒市场－全球产业规模、份额、趋势、机会和预测，按工作流程、按定序类型、按应用、按最终用户、按地区和竞争情况细分，2020 年至 2030 年

2024年，全球次世代定序试剂盒市场规模为82.4亿美元，预计2030年将达到132.2亿美元，预测期内复合年增长率为8.34%。随着基因组技术在临床诊断、学术研究和药物开发领域的应用日益广泛，全球次世代定序 (NGS) 试剂盒市场持续快速成长。 NGS试剂盒是简化复杂定序工作流程的关键组件，能够以极快的速度和精确度对DNA和RNA进行高通量分析。这些试剂盒在癌症基因组学、罕见遗传疾病筛检、非侵入性产前检测 (NIPT) 和病原体检测等应用中尤其重要。

市场成长的一个关键驱动力是个人化医疗需求的不断增长，其中NGS能够识别患者特异性基因突变，从而指导个人化治疗方案。这种向个人化治疗的转变在肿瘤学领域尤其明显，NGS越来越多地用于肿瘤分析和监测治疗反应。例如，2023年11月，Yourgene Health和PacBio宣布合作，以增强长读长定序工作流程。 PacBio批准了Yourgene的LightBench仪器，用于高效筛选长DNA片段的大小。此次合作旨在简化定序流程并提高基因组分析的准确性，支持研究和临床诊断领域的高阶应用。近年来，定序成本大幅下降，使得全球中小型实验室和诊所更容易获得这些技术。

关键市场驱动因素

遗传疾病和癌症盛行率不断上升

主要市场挑战

高昂的初始设定和营运成本

主要市场趋势

定序技术的进步

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球下一代定序试剂盒市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依工作流程（文库製备、簇生成、定序试剂盒）
  • 依定序类型（WES 和 WGS、标靶定序、长读定序、其他定序）
  • 依应用（肿瘤学、罕见疾病、遗传性疾病、生殖健康、其他）
  • 按最终用户（学术和研究机构、製药和生物技术公司、临床和诊断实验室等）
  • 按地区（北美、欧洲、亚太、南美、中东和非洲）
  • 按公司分类（2024）
• 市场地图

第六章：北美次世代定序试剂盒市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲下一代定序试剂盒市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区次世代定序试剂盒市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美下一代定序试剂盒市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲下一代定序试剂盒市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：全球下一代定序试剂盒市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Bio-Rad Laboratories, Inc.
• BGI Group.
• Creative Biogene.
• Danaher.
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Illumina, Inc.
• Oxford Nanopore Technologies plc.
• Pacific Biosciences of California, Inc.
• PerkinElmer Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

Global Next Generation Sequencing Kits Market was valued at USD 8.24 billion in 2024 and is expected to reach USD 13.22 billion by 2030 with a CAGR of 8.34% during the forecast period. The Global Next Generation Sequencing (NGS) Kits Market continues to grow rapidly as the use of genomic technologies becomes more widespread across clinical diagnostics, academic research, and pharmaceutical development. NGS kits are essential components that streamline complex sequencing workflows, enabling high-throughput analysis of DNA and RNA with exceptional speed and accuracy. These kits are particularly vital in applications such as cancer genomics, rare genetic disorder screening, non-invasive prenatal testing (NIPT), and pathogen detection.

A key driver of market growth is the rising demand for personalized medicine, where NGS enables the identification of patient-specific genetic mutations to guide tailored treatment plans. This shift toward individualized care is particularly evident in oncology, where NGS is increasingly used for tumor profiling and monitoring treatment response. For instace, in November 2023, Yourgene Health and PacBio announced a collaboration to enhance long-read sequencing workflows. PacBio approved Yourgene's LightBench instrument for efficient size selection of long DNA fragments. This partnership aims to streamline sequencing processes and improve accuracy in genomic analysis, supporting advanced applications in research and clinical diagnostics. The cost of sequencing has dropped significantly in recent years, making these technologies more accessible to small and mid-sized laboratories and clinics globally.

Key Market Drivers

Increasing Prevalence of Genetic Disorders and Cancer

The increasing prevalence of genetic disorders and cancer is a significant driver propelling the growth of the Global Next Generation Sequencing (NGS) Kits Market. Genetic disorders, including conditions such as cystic fibrosis, sickle cell anemia, and Duchenne muscular dystrophy, are affecting a growing portion of the global population. At the same time, cancer remains one of the leading causes of death worldwide, with an estimated 20 million new cancer cases diagnosed globally in 2022, according to the World Health Organization. Also, According to WHO 2025, anemia is a major global health concern, especially among young children, pregnant women, and menstruating girls and women. It disproportionately affects rural, low-income, and uneducated populations in low- and lower-middle-income countries. In 2019, anemia caused 50 million healthy life years lost, mainly due to iron deficiency, thalassaemia, sickle cell trait, and malaria. Early detection and accurate diagnosis are critical in managing these conditions, and NGS technologies are revolutionizing how clinicians identify genetic mutations and oncogenic alterations. NGS kits enable the rapid, comprehensive analysis of entire genomes or targeted gene panels, allowing researchers and healthcare professionals to detect pathogenic variants with high precision. In oncology, NGS is used extensively to perform tumor profiling, assess minimal residual disease, and guide treatment selection based on the genetic characteristics of individual tumors. This level of insight is not possible with traditional diagnostic methods. As a result, hospitals and diagnostic laboratories are increasingly incorporating NGS into routine testing protocols.

The rise in inherited genetic disorders has underscored the need for carrier screening, newborn screening, and prenatal testing-all areas where NGS kits play a central role. The growing use of non-invasive prenatal testing (NIPT) and whole-exome or whole-genome sequencing in pediatrics further amplifies demand. The public and private investments in genomics research aimed at understanding genetic diseases have boosted the deployment of NGS kits in research settings. With the global burden of cancer and genetic disorders on the rise, the demand for accurate, efficient, and cost-effective diagnostic tools will continue to accelerate, making NGS kits indispensable in both clinical and research environments.

Key Market Challenges

High Initial Setup and Operational Costs

High initial setup and operational costs represent one of the most significant challenges in the Global Next Generation Sequencing (NGS) Kits Market, particularly for smaller laboratories, research institutions, and healthcare facilities in low- and middle-income countries. While the cost of sequencing per genome has decreased over the years, the overall investment required to establish and maintain an NGS infrastructure remains substantial. This includes the purchase of high-throughput sequencing platforms, automated sample preparation systems, data analysis tools, and the NGS kits themselves, which are often costly due to their complexity and specificity. Beyond hardware and consumables, operational costs include regular maintenance, calibration, and the need for skilled personnel to manage sequencing workflows and interpret complex genomic data. In addition, storage and management of large datasets generated by NGS require robust IT infrastructure, including secure servers and advanced bioinformatics software-further adding to the total cost burden. These financial barriers can delay or even prevent the adoption of NGS technologies in many clinical and research settings, despite growing demand for advanced genomic testing in oncology, rare diseases, and infectious disease surveillance. The high cost structure also limits the ability of healthcare systems to offer NGS-based testing at scale, particularly in public health programs.

To address these challenges, market players are exploring cost-reduction strategies such as miniaturized sequencing platforms, simplified library preparation kits, and cloud-based bioinformatics solutions. The broader adoption depends on public-private partnerships, government subsidies, and expanded reimbursement frameworks that help offset upfront costs and make NGS technologies more accessible globally.

Key Market Trends

Advancements in Sequencing Technologies

Advancements in sequencing technologies are significantly shaping the future of the Global Next Generation Sequencing (NGS) Kits Market. Over the past decade, NGS has seen rapid progress in both its capabilities and accessibility, leading to a surge in applications across clinical diagnostics, research, and personalized medicine. These innovations are not only enhancing the accuracy and throughput of NGS but also reducing the cost and time required for sequencing, making it more accessible to a broader range of laboratories and healthcare providers. One of the most notable advancements is the development of single-molecule sequencing technologies. Companies like Oxford Nanopore Technologies have introduced platforms that sequence DNA directly without the need for amplification, allowing for longer reads and improved resolution of complex genomic regions. This is particularly valuable in areas like structural variation detection and de novo genome assembly, which were challenging with traditional sequencing technologies.

Another significant advancement is short-read sequencing improvements, especially by market leaders like Illumina, which have optimized their platforms for better accuracy, speed, and cost-effectiveness. These advancements are critical for large-scale projects and clinical applications, where speed and precision are essential. The introduction of long-read sequencing technologies is enabling more detailed and comprehensive genome analyses, allowing for the detection of rare mutations and previously undetectable genomic variations. The emergence of portable and miniaturized sequencing devices is also transforming the NGS market. These compact devices, such as the MinION from Oxford Nanopore, offer real-time sequencing capabilities, making genomic analysis possible in resource-limited settings and field-based applications. The integration of AI and machine learning into sequencing workflows is enhancing data analysis. These technologies are improving the ability to identify meaningful genetic variants and speed up the process of data interpretation, which is a critical factor in the clinical application of NGS technologies. These advancements are not only enhancing the capabilities of NGS kits but are also driving their broader adoption across a variety of industries, from healthcare to agriculture and environmental science, making NGS an indispensable tool for the future.

Key Market Players

• Bio-Rad Laboratories, Inc.
• BGI Group.
• Creative Biogene
• Danaher.
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Illumina, Inc.
• Oxford Nanopore Technologies plc.
• Pacific Biosciences of California, Inc.
• PerkinElmer Inc.

Report Scope:

In this report, the Global Next Generation Sequencing Kits Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Sequencing Kits Market, By Workflow:

• Library Preparation
• Cluster Generation
• Sequencing Reagents Kits

Next Generation Sequencing Kits Market, By Sequencing Type:

• WES and WGS
• Targeted Sequencing
• Long Read Sequencing
• Other Sequencing

Next Generation Sequencing Kits Market, By Application:

• Oncology
• Rare Diseases
• Genetic Disorders
• Reproductive Health
• Others

Next Generation Sequencing Kits Market, By End User:

• Academic and Research Institutions
• Pharmaceutical and Biotechnology Companies
• Clinical and Diagnostic Laboratories
• Others

Next Generation Sequencing Kits Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Plasma Exchange Market.

Available Customizations:

Global Next Generation Sequencing Kits Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next Generation Sequencing Kits Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Workflow (Library Preparation, Cluster Generation, Sequencing Reagents Kits)
  • 5.2.2. By Sequencing Type (WES and WGS, Targeted Sequencing, Long Read Sequencing, Other Sequencing)
  • 5.2.3. By Application (Oncology, Rare Diseases, Genetic Disorders, Reproductive Health, Others)
  • 5.2.4. By End User (Academic and Research Institutions, Pharmaceutical and Biotechnology Companies, Clinical and Diagnostic Laboratories, Others)
  • 5.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Next Generation Sequencing Kits Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Workflow (Library Preparation, Cluster Generation, Sequencing Reagents Kits)
  • 6.2.2. By Sequencing Type (WES and WGS, Targeted Sequencing, Long Read Sequencing, Other Sequencing)
  • 6.2.3. By Application (Oncology, Rare Diseases, Genetic Disorders, Reproductive Health, Others)
  • 6.2.4. By End User (Academic and Research Institutions, Pharmaceutical and Biotechnology Companies, Clinical and Diagnostic Laboratories, Others)
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Next Generation Sequencing Kits Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Workflow
      • 6.3.1.2.2. By Sequencing Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Next Generation Sequencing Kits Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Workflow
      • 6.3.2.2.2. By Sequencing Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Next Generation Sequencing Kits Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Workflow
      • 6.3.3.2.2. By Sequencing Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Next Generation Sequencing Kits Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Workflow (Library Preparation, Cluster Generation, Sequencing Reagents Kits)
  • 7.2.2. By Sequencing Type (WES and WGS, Targeted Sequencing, Long Read Sequencing, Other Sequencing)
  • 7.2.3. By Application (Oncology, Rare Diseases, Genetic Disorders, Reproductive Health, Others)
  • 7.2.4. By End User (Academic and Research Institutions, Pharmaceutical and Biotechnology Companies, Clinical and Diagnostic Laboratories, Others)
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Next Generation Sequencing Kits Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Workflow
      • 7.3.1.2.2. By Sequencing Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Next Generation Sequencing Kits Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Workflow
      • 7.3.2.2.2. By Sequencing Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Next Generation Sequencing Kits Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Workflow
      • 7.3.3.2.2. By Sequencing Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Next Generation Sequencing Kits Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Workflow
      • 7.3.4.2.2. By Sequencing Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Next Generation Sequencing Kits Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Workflow
      • 7.3.5.2.2. By Sequencing Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Next Generation Sequencing Kits Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Workflow (Library Preparation, Cluster Generation, Sequencing Reagents Kits)
  • 8.2.2. By Sequencing Type (WES and WGS, Targeted Sequencing, Long Read Sequencing, Other Sequencing)
  • 8.2.3. By Application (Oncology, Rare Diseases, Genetic Disorders, Reproductive Health, Others)
  • 8.2.4. By End User (Academic and Research Institutions, Pharmaceutical and Biotechnology Companies, Clinical and Diagnostic Laboratories, Others)
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Next Generation Sequencing Kits Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Workflow
      • 8.3.1.2.2. By Sequencing Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Next Generation Sequencing Kits Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Workflow
      • 8.3.2.2.2. By Sequencing Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Next Generation Sequencing Kits Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Workflow
      • 8.3.3.2.2. By Sequencing Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Next Generation Sequencing Kits Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Workflow
      • 8.3.4.2.2. By Sequencing Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Next Generation Sequencing Kits Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Workflow
      • 8.3.5.2.2. By Sequencing Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Next Generation Sequencing Kits Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Workflow (Library Preparation, Cluster Generation, Sequencing Reagents Kits)
  • 9.2.2. By Sequencing Type (WES and WGS, Targeted Sequencing, Long Read Sequencing, Other Sequencing)
  • 9.2.3. By Application (Oncology, Rare Diseases, Genetic Disorders, Reproductive Health, Others)
  • 9.2.4. By End User (Academic and Research Institutions, Pharmaceutical and Biotechnology Companies, Clinical and Diagnostic Laboratories, Others)
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Next Generation Sequencing Kits Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Workflow
      • 9.3.1.2.2. By Sequencing Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Next Generation Sequencing Kits Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Workflow
      • 9.3.2.2.2. By Sequencing Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Next Generation Sequencing Kits Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Workflow
      • 9.3.3.2.2. By Sequencing Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Next Generation Sequencing Kits Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Workflow (Library Preparation, Cluster Generation, Sequencing Reagents Kits)
  • 10.2.2. By Sequencing Type (WES and WGS, Targeted Sequencing, Long Read Sequencing, Other Sequencing)
  • 10.2.3. By Application (Oncology, Rare Diseases, Genetic Disorders, Reproductive Health, Others)
  • 10.2.4. By End User (Academic and Research Institutions, Pharmaceutical and Biotechnology Companies, Clinical and Diagnostic Laboratories, Others)
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Next Generation Sequencing Kits Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Workflow
      • 10.3.1.2.2. By Sequencing Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Next Generation Sequencing Kits Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Workflow
      • 10.3.2.2.2. By Sequencing Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Next Generation Sequencing Kits Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Workflow
      • 10.3.3.2.2. By Sequencing Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Next Generation Sequencing Kits Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bio-Rad Laboratories, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Product Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Key Personnel
• 15.2. BGI Group.
• 15.3. Creative Biogene.
• 15.4. Danaher.
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. Hologic, Inc.
• 15.7. Illumina, Inc.
• 15.8. Oxford Nanopore Technologies plc.
• 15.9. Pacific Biosciences of California, Inc.
• 15.10. PerkinElmer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer